Stephan H. Rosenkranz
Elite in Hypertension

Stephan H. Rosenkranz

Kerpener Str. 62, 
Koeln, NW, DE 
Elite in Hypertension
Kerpener Str. 62, 
Koeln, NW, DE 
OverviewLocationsClinical Research

Overview

Stephan Rosenkranz practices in Koeln, Germany. Mr. Rosenkranz is rated as an Elite expert by MediFind in the treatment of Hypertension. His top areas of expertise are Pulmonary Hypertension, Hypertension, Pulmonary Embolism, Angioplasty, and Thrombectomy.

His clinical research consists of co-authoring 259 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 167 articles and participated in 2 clinical trials in the study of Hypertension.

Gender
Male

Locations

Kerpener Str. 62, Koeln, NW 50937, Germany
Other Locations
Kerpener Street. 62, Koeln, NW 50937, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

259 Total Publications

La3CuTe5: A Narrow-Gap Semiconductor with Indirect Gap and Dual-Regime Thermally Activated Transport.
La3CuTe5: A Narrow-Gap Semiconductor with Indirect Gap and Dual-Regime Thermally Activated Transport.
Journal: Inorganic chemistry
Published: October 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rosenkranz's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 33 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile